CapsoVision's sales barely move as AI reading aid reaches US market and losses widen

CapsoVision's commercial story for the third quarter was one of stasis rather than acceleration: sales of $3.6M, against $3.5M a year before, while the company lost $7.3M. The figures were reported on 12 November 2026.

The potential change of pace lies in software. The US Food and Drug Administration cleared AI Highlights, an artificial-intelligence tool that helps clinicians read images from the CapsoCam Plus capsule endoscope, on 25 September. The company started selling it in the US on 2 November, so none of the quarter's revenue reflects a full period of availability. The facts available do not include pricing, reimbursement or any early customer uptake.

CapsoVision also said it has finished enrolling patients in its CapsoCam Colon study and is aiming to file a 510(k) by the end of 2026. That is the FDA pathway in which a device maker demonstrates that its product is substantially equivalent to one already legally on the market. Whether and when clearance follows will rest on the agency's review.

To fund operations, the company raised roughly $17.8M net in September through a registered direct offering. The summary on file does not say how the money will be spent, nor how long it extends the company's runway.